This is highlighted by the drug combination of dabrafenib plus trametinib, which is indicated in unresectable or metastatic solid tumors with a BRAFV600E mutation, except in colorectal cancer, due to intrinsic resistance to BRAF inhibition [8]. The gene discussed is BRAF; the disease is colorectal cancer.